These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29230931)

  • 41. C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes.
    Nishimura T; Meguro S; Sekioka R; Tanaka K; Saisho Y; Irie J; Tanaka M; Kawai T; Itoh H
    Diabetes Res Clin Pract; 2015 Jun; 108(3):441-7. PubMed ID: 25795273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors associated with potential over- and undertreatment of hyperglycaemia and annual measurement of HbA
    Tran AT; Berg TJ; Mdala I; Gjelsvik B; Cooper JG; Sandberg S; Claudi T; Jenum AK
    Diabet Med; 2021 Aug; 38(8):e14500. PubMed ID: 33354827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System.
    Mast MR; Walraven I; Hoekstra T; Jansen AP; van der Heijden AA; Elders PJ; Heine RJ; Dekker JM; Nijpels G; Hugtenburg JG
    Diabet Med; 2016 Jun; 33(6):794-802. PubMed ID: 26946450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes.
    Stein CM; Kramer CK; Zinman B; Choi H; Opsteen C; Retnakaran R
    Diabet Med; 2015 May; 32(5):645-52. PubMed ID: 25495067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
    Punthakee Z; Miller ME; Simmons DL; Riddle MC; Ismail-Beigi F; Brillon DJ; Bergenstal RM; Savage PJ; Hramiak I; Largay JF; Sood A; Gerstein HC;
    Diabetologia; 2014 Oct; 57(10):2030-7. PubMed ID: 24985147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The high prevalence of malnutrition in elderly diabetic patients: implications for anti-diabetic drug treatments.
    Vischer UM; Perrenoud L; Genet C; Ardigo S; Registe-Rameau Y; Herrmann FR
    Diabet Med; 2010 Aug; 27(8):918-24. PubMed ID: 20653750
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study.
    Hage C; Norhammar A; Grip L; Malmberg K; Sarkar N; Svane B; Rydén L
    Diab Vasc Dis Res; 2009 Apr; 6(2):71-9. PubMed ID: 20368196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients.
    Ajjan RA; Abougila K; Bellary S; Collier A; Franke B; Jude EB; Rayman G; Robinson A; Singh BM
    Diab Vasc Dis Res; 2016 May; 13(3):211-9. PubMed ID: 27000105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43).
    Satoh J; Andersen M; Bekker Hansen B; Larsen Thorsted B; Tutkunkardas D; Zacho M; Maegawa H
    PLoS One; 2018; 13(9):e0198160. PubMed ID: 30226870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes.
    Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP
    Neth J Med; 1999 Feb; 54(2):63-9. PubMed ID: 10079680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phenotype, genotype and glycaemic variability in people with activating mutations in the ABCC8 gene: response to appropriate therapy.
    Reilly F; Sanchez-Lechuga B; Clinton S; Crowe G; Burke M; Ng N; Colclough K; Byrne MM
    Diabet Med; 2020 May; 37(5):876-884. PubMed ID: 31562829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
    Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact and duration effect of telemonitoring on ΗbA1c, BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study.
    Fountoulakis S; Papanastasiou L; Gryparis A; Markou A; Piaditis G
    Hormones (Athens); 2015; 14(4):632-43. PubMed ID: 26188234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement.
    Jalving AC; Gant CM; Binnenmars SH; Soedamah-Muthu SS; Bakker SJL; Navis G; Laverman GD
    Diabetes Obes Metab; 2018 Oct; 20(10):2494-2499. PubMed ID: 29862616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.